TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06347965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low load blood flow restriction training
Description: Low load blood flow restriction training will be conducted on the subjects three times a week. Each training session includes upper and lower limb training, with 4 groups trained and repeated 30, 15, 15, and 15 times for each group. Train for a total of 12 weeks.The resistance strength will remain at 30% RM for weeks 1-12.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive resistance training group
Description: The subjects will undergo progressive resistance training three days a week, three groups per day, with each group repeating 10 times. Training includes upper and lower limbs. The resistance load increases over time, with a resistance load of 30% RM for weeks 1-4, 50% RM for weeks 5-8, and 70% RM for weeks 9-12.
Study: NCT05601050

Intervention type: OTHER
Intervention: There is no intervention
Description: There is no intervention
Study: NCT04925947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: KN046 will be given intravenously at 5 mg/kg every 2 weeks. A cycle is defined as 2 treatments (28 days). Treatment will be given until progression, excessive toxicity, or up to two years.
Study: NCT05721196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally adapted Psychoeducation (CaPE)
Description: This intervention consisted of 12 psychoeducation sessions, one session per week, that would be administered on an individual patient basis and to be added to treatment as usual. Each session lasted for approximately 1 h, beginning with a 20-30 min presentation on the topic of the day, followed by a related exercise (e.g., drawing a life chart or compiling a list of potential triggers for relapse). The content is a reduced and modified version of the Barcelona Psychoeducation Program for bipolar disorders.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TaU)
Description: This group of patients will receive routine treatment, which in Nigeria means attending the outpatient clinic and taking prescribed medication.
Study: NCT04880681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel needle (18 G, 25 cm with 19 mm sample notch) in a new actuator.
Description: Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient.
Study: NCT05755620

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Chloride, 0.9%
Description: 0.9% Sodium Chloride Injection
Study: NCT04880681

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Tru Cut biopsy needle (Argon 18G, 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator (Möller Medical Blue RBG-1000-10-1000)
Description: Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient.
Study: NCT05109078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]- Rongliflozin
Description: Patients will receive single dose of orally \[14C\]- Rongliflozin on Day 1
Study: NCT06453863

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Greater plantar feedback shoes
Description: Shoes providing enhanced plantar feedback

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neutral gym shoes
Description: Regular gym shoes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Barefoot
Description: For the acute evaluation, barefoot will be considered as an active comparator for enhanced plantar feedback
Study: NCT05833568

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial alternative current stimulation
Description: GTEN 200 (Magstim-EGI, OREGON, USA). The current will be administered via an amplifier connected to an EEG system of 128-Channel Geodesic Sensor Net (Magstim-EGI, Oregon, USA) with sponge-based electrode nets.~tACS stimulation will be applied for 20 minutes for 5 consecutive days via a bilateral electrode montage of 5 electrodes per hemisphere over parieto-occipital cortical sites. Specific stimulation electrodes for both conditions will be: \[right hemisphere: E83, E90, E96, E84, E91\] and for the \[left hemisphere: E58, E65, E70, E66, E59\]. The intensity of the applied alternative current (AC) will be a maximum of 1 mA peak-to-peak. The stimulation frequency will be adjusted to 10 Hz (median value of the alpha frequency band) for the tACS condition.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM Transcranial alternative current stimulation
Description: GTEN 200 (Magstim-EGI, OREGON, USA). The current will be administered via an amplifier connected to an EEG system of 128-Channel Geodesic Sensor Net (Magstim-EGI, Oregon, USA) with sponge-based electrode nets.~SHAM stimulation will be applied for a 2-minute ramp-up, then the current will stop for 20 minutes, followed by a 2-minute ramp-down. This will be applied for 5 consecutive days via a bilateral electrode montage of 5 electrodes per hemisphere over parieto-occipital cortical sites. Specific stimulation electrodes for both conditions will be: \[right hemisphere: E83, E90, E96, E84, E91\] and for the \[left hemisphere: E58, E65, E70, E66, E59\]. The intensity of the applied alternative current (AC) will be a maximum of 1 mA peak-to-peak. The stimulation frequency will be adjusted to 10 Hz (median value of the alpha frequency band) for the ramp-up and down in the SHAM conditions.
Study: NCT05665660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE
Description: CARE is a culturally tailored mammography education module.
Study: NCT03877991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD-sesame oil capsule
Description: A capsule containing cannabidiol dissolved in sesame oil and surfactant vehicle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD-LNL capsule
Description: A capsule containing Cannabidiol dissolved in self nano emulsifying formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD powder form capsule
Description: Powder of Cannabidiol filled in a hard gelatin capsule, without formulation.
Study: NCT06417736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate 40 MG
Description: 160mg/one time/day
Study: NCT05755620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Chloride, 0.9%
Description: 0.9% Sodium Chloride Injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Chloride, 0.9%
Description: 0.9% Sodium Chloride Injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Chloride, 0.9%
Description: 0.9% Sodium Chloride Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUNPF099-00-VP (H1ssF_3928)
Description: The vaccine consists of modified nucleoside messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNP), comprised of four lipid components: (ALC-307 (ionizable lipid), DSPC, cholesterol, and ALC-0159 \[PEG lipid\]).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUNPF099-00-VP (H1ssF_3928)
Description: The vaccine consists of modified nucleoside messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNP), comprised of four lipid components: (ALC-307 (ionizable lipid), DSPC, cholesterol, and ALC-0159 \[PEG lipid\]).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUNPF099-00-VP (H1ssF_3928)
Description: The vaccine consists of modified nucleoside messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNP), comprised of four lipid components: (ALC-307 (ionizable lipid), DSPC, cholesterol, and ALC-0159 \[PEG lipid\]).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUNPF099-00-VP (H1ssF_3928)
Description: The vaccine consists of modified nucleoside messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNP), comprised of four lipid components: (ALC-307 (ionizable lipid), DSPC, cholesterol, and ALC-0159 \[PEG lipid\]).
Study: NCT06048120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2701250 IV
Description: Single does, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: Matching placebo for BAY2701250 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2701250 SC
Description: Single dose, subcutaneous injection will be administered into abdominal subcutaneous fat tissue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: Matching placebo for BAY2701250 SC
Study: NCT06207305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Given by PO
Study: NCT05665660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE + COACH
Description: CARE + COACH is a culturally tailored mammography education module + access to an Apache paraprofessional women's health coach who functions as a patient navigator
Study: NCT06207305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given by PO
Study: NCT05767021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC
Study: NCT06193863

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: At the discretion of the treating physician, based on the recommendations written in the local product information.
Study: NCT06430385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION440
Description: ION440 will be administered by intrathecal bolus (ITB) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION440
Description: ION440 will be administered by intrathecal bolus (ITB) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION440
Description: ION440 will be administered by intrathecal bolus (ITB) injection.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: An LP will be performed with CSF collection but will not be followed by the administration of study treatment by ITB injection.
Study: NCT05669547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dual hormone fully closed loop (DHFCL)
Description: dual hormone fully closed loop consisting of an algorithm, sensors and both insulin and glucagon infusion.
Study: NCT04660812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB680
Description: AB680 is a cluster of differentiated CD73 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is a dual adenosine receptor (A2aR and A2bR) antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is a dual adenosine receptor (A2aR and A2bR) antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is a fully human anti-PD-1 monoclononal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is a fully human anti-PD-1 monoclononal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is administered as part of standard chemotherapy regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is administered as part of standard chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: m-FOLFOX-6 regimen
Description: mFOLFOX-6 regimen is administered as part of standard chemotherapy regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: m-FOLFOX-6 regimen
Description: mFOLFOX-6 regimen is administered as part of standard chemotherapy regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Regorafenib is adminstered as part of standard chemotherapy regimen
Study: NCT06486844

Intervention type: DRUG
Intervention: Vericiguat (Verquvo, BAY1021189)
Description: Vericiguat was given following routine clinical practice.
Study: NCT04975308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlunestrant
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlunestrant
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Administered IM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally.
Study: NCT06129188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam is an ultra-short acting benzodiazepine medication. Benzodiazepines are a class of drug that directly interact with gamma-aminobutyric acid (GABA) and modifiable chloride channels through polysynaptic pathway inhibition. The anxiolytic properties of benzodiazepines make them useful as sedatives.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Standard of care usage of the intravenous anesthetic agent propofol to achieve adequate sedation conditions for the procedure.
Study: NCT05564221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH35324
Description: Subcutaneous injection of YH35324

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of None of active ingredient

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Subcutaneous injection of Omalizumab
Study: NCT05933681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neural recordings and stimulation
Description: Neural activities from the dorsolateral prefrontal cortex and implanted DBS generator will be recorded, during resting and working memory tasks, and with the DBS target turned on and off.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neural recordings and stimulation
Description: Neural activities from the dorsolateral prefrontal cortex and implanted DBS generator will be recorded, during resting and working memory tasks, and with the DBS target turned on and off.
Study: NCT04856462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Support
Description: Structured education is provided every other week (biweekly) to family caregivers over the course of 12 weeks, along with facilitated video-teleconferencing group meetings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone Call
Description: Participants will participate in an unstructored support group phone call
Study: NCT03746535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elagolix
Description: Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days.
Study: NCT05465616

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viome's Precision Nutrition Program (VPNP)
Description: Nutrition, diet, and possible coaching through Viome application. Precision supplement based on the participants microbiome sample results.
Study: NCT05337228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C006 Peri inj.
Description: IN-C006 peri inj. will be injected continuously for 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RPN301
Description: RPN301 will be injected continuously for 3 days.
Study: NCT06049862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MaRiTensi App
Description: MaRiTensi is a mobile health-based hypertension self-management application used on Android smartphones.~MariTensi provides facilities for recording blood pressure, BMI, activity, examination results, education about hypertension, consultations, reminders and community chat.
Study: NCT04632810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic low energy diet
Description: Participants will follow a low energy diet, with 1200 kcal per day. Carbohydrates 75g (25E%), protein 60 g (20E%), fat 73 g (55E%) in 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-ketogenic low energy diet
Description: Participants will follow a low energy diet, with 1200 kcal per day. Carbohydrates 180g (60E%), protein 60 g (20E%), fat 27 g (20E%), in 8 weeks
Study: NCT06436560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STRIVE Peer Support Intervention
Description: A virtual group-based peer support intervention led by trans peers who have had genital gender-affirming surgery.
Study: NCT05905770

Intervention type: DRUG
Intervention: Alemtuzumab Injection [Campath]
Description: Alemtuzumab 1mg/kg
Study: NCT04449991

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repeat kidney biopsy
Description: Intensification of immunosuppression if NIH AI \> 3
Study: NCT06084234

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GALAD
Description: GALAD is a 3 biomarker panel incorporating AFP, AFP-L3% and DCP (all FDA approved), with patient age and sex.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Liver Ultrasound with or without AFP
Description: This intervention consists of current standard of care ultrasound based surveillance with or without alpha-fetoprotein measurement.
Study: NCT05492344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized ventilation
Description: Patients who are randomized for personalized ventilation with FOCAL ARDS will receive the following ventilator settings:~* Positive end-expiratory pressure (PEEP) ≤ 9 cm water (H2O)~* Tidal volume: 6 to 8 mL/kg predicted body weight (PBW)~* Daily prone positioning~LUS will be repeated every 48-72 hours in supine position for the focal ARDS patients to assess whether they have developed non-focal ARDS during admission. In that case, patients will from then on be treated according non-focal personalized treatment protocol.~Patients who are randomized for personalized ventilation with Non-FOCAL ARDS will receive the following ventilator settings:~* PEEP ≥ 15 cm H2O~* Tidal volume: 4 to 6 mL/kg PBW~* Daily recruitment maneuver

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patient who are randomized in the control group will receive standard care~* Tidal volume: 6 mL/kg PBW~* PEEP and FiO2 according to the low PEEP and high fraction of inspired oxygen (FiO2) table of the AlVEOLI study~* Prone positioning if the Partial Pressure of Oxygen (PaO2) /FiO2 ratio is \< 150 mmHg
Study: NCT04904328

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lumishade® Active Lens
Description: Migraine episodes are often triggered or exacerbated by environmental factors, particularly light. Active lens has been designed by blocking particular range of wavelength and hypothetically alleviate symptoms of migraine and thus either treat or prevent migraine headaches from occurring.~(Note, we are reluctant to write any further information around the devices on this public record while the study is active to ensure we maintain the blind of the trial.)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Lumishade® Sham Lens
Description: Lumishade® Sham lens has been designed as inactive and not blocking particular range of wavelength. Thus, it will not alleviate or prevent symptoms of migraine.~(Note, we are reluctant to write any further information around the devices on this public record while the study is active to ensure we maintain the blind of the trial.)
Study: NCT06197750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular stimulation
Description: Vestibular stimulation by swing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General strengthening exercises
Description: General strengthening exercises
Study: NCT05881915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: phenylephrine infusion at rate of 0.4 mcg/Kg/min. (10 mg /1 mL) will be diluted to reach a final concentration of 10 mcg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: epinephrine infusion dose of 0.03 mcg/Kg/min. epinephrine (1mg/ 1mL ampoule) will be diluted to reach a final concentration of 10 mcg/ml.
Study: NCT05845008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/Naproxen Sodium Fixed Combination
Description: Acetaminophen/naproxen sodium fixed combination tablets, oral.
Study: NCT06301594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic simple swallowing training
Description: Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week
Study: NCT05499598

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: Modified minimally invasive surgical technique with PRF and vitamins A and C
Description: Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of fresh blood will be drawn by venipuncture of the antecubital vein and collected into a blood collection tube without anticoagulant. Ascorbic Acid will be added to the fresh blood to achieve a concentration of 250 μg/ml, Retinol will also be added to achieve a concentration of 20 μmol/L. The resultant PRF clot will be placed into the intra-osseous defect.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified minimally invasive surgical technique with PRF
Description: Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of fresh blood will be drawn by venipuncture of the antecubital vein and collected into a blood collection tube without anticoagulant. The resultant PRF clot will be placed into the intra-osseous defect.
Study: NCT05526781

Intervention type: DEVICE
Intervention: Clareon monofocal Intraocular lens (toric and non-toric models)
Description: Bilateral implantation of the Clareon monofocal Intraocular lens (toric and non-toric models) with the Monarch IV inserter